No evidence of benefits from H1 antihistamines for eczema

There was no consistent evidence that H1 AH treatments were effective as add‐on therapy for eczema when compared with placebo (low and moderate-quality evidence). However, fexofenadine probably led to a small improvement in patient‐assessed pruritus, with probably no significant difference in the amount of treatment used to prevent eczema flares. Cetirizine was no better than placebo in terms of physician‐assessed clinical signs nor patient‐assessed symptoms, and there was no evidence that loratadine was more beneficial than placebo, although all interventions seemed safe. Trial duration was between 3 days and 18 months. Researchers studied 13 different H1 AH treatments.